Galapagos reported EUR122.32M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
argenx SE USD 744.12M 92.38M Jun/2025
AstraZeneca USD 10.95B 1.04B Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
Genmab DKK 565M 38M Jun/2025
Gilead Sciences USD 4.35B 80M Jun/2025
GlaxoSmithKline GBP 5.96B 663M Jun/2025
GRIFOLS EUR 1.54B 24.64M Jun/2025
Hikma Pharmaceutical USD 1.31B 63M Dec/2024
Incyte USD 904.7M 56.97M Jun/2025
Merck EUR 4.22B 49M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
Roche Holding CHF 11.43B 1.48B Dec/2024
Sanofi EUR 9.02B 702M Jun/2025
UCB EUR 2.36B 108M Dec/2024
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025